Accessibility Menu
Jaguar Health logo

Jaguar Health

(NASDAQ) JAGX

Current Price$1.07
Market Cap$6.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2017)-100%
5 Year-100%
1 Year-98%
1 Month-42%
Jaguar Health last closing stock price
MetricPriceDate
Last closeUSD 1.342026-07-16
Jaguar Health stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-43.67%USD 2.372026-07-09
1 month-42.21%USD 2.312026-06-16
3 month-90.37%USD 13.862026-04-17
Year to date-95.9%USD 32.592025-12-31
1 year-98.44%USD 85.402025-07-16
3 year-100%USD 28,875.002023-07-17
5 year-100%USD 15,474,375.002021-07-16
Since inception-100%USD 5,900,000,000.002017-08-01

Jaguar Health Financials at a Glance

Market Cap

$6.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$29.57M

Net Income (TTM)

-$34.12M

EPS (TTM)

-$708.72

P/E Ratio

0.00

Dividend

$0.00

Beta (Volatility)

1.66 (High)

Price

$1.07

Volume

175,637.379

Open

$1.27

Previous Close

$1.34

Daily Range

$1.02 - $1.31

52-Week Range

$1.02 - $92.75

Estimated Earnings Date

Aug 13, 2026

JAGX News

Growth - GettyImages-1135598290

Why Jaguar Health Stock Skyrocketed 49% Today

Joe TenebrusoJan 8, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Jaguar Health

Jaguar Health makes medicines for people and animals with chronic diarrhea. Its main product helps adults with HIV/AIDS manage noninfectious diarrhea. The company also develops treatments for rare digestive diseases and animal health needs.

What’s in the Medicine Cabinet?

  • Mytesi (Human Health, ~98% revenue): Prescription tablets for adults with HIV/AIDS to manage noninfectious diarrhea.
  • Gelclair: Oral gel for pain relief in cancer patients with mouth sores.
  • Crofelemer Pipeline: Under study for cancer therapy-related diarrhea, rare childhood digestive disorders, and short bowel syndrome.
  • Canalevia (Animal Health, ~1% revenue): Tablets for dogs with diarrhea from chemotherapy or exercise.
  • Neonorm: Plant-based digestive support for calves and foals.

Growth and Expansion: The Jaguar’s Journey

  • 2024: Launched Gelclair in the US for cancer-related mouth pain.
  • 2026: Signed US licensing deal with Future Pak for Mytesi and Canalevia-CA1, securing $16 million upfront.
  • Expanded manufacturing with Alivus (India) and Indena (Italy).
  • Formed joint venture with Filament Health (Magdalena Biosciences) for plant-based mental health drugs.
  • Ongoing clinical trials for new uses of crofelemer in rare digestive diseases.

What Makes Jaguar Health Stand Out?

Jaguar Health focuses on plant-based medicines for both humans and animals. Its products target rare digestive diseases, offering regulatory exclusivity in some cases. The company manages a global supply chain and partners with specialty pharmacies for distribution.

Five Things You Need to Know

  • Total revenue was $11.5 million in 2025, down 1.5% from 2024.
  • Net loss reached $54.0 million in 2025, up 37.6% year-over-year.
  • Two specialty pharmacies made up 82% of 2025 revenue.
  • Cash at year-end 2025 was $968,000, with $42.5 million in debt.
  • Research and development spending rose 50.9% to $25.0 million in 2025.

Bottom Line

Jaguar Health has evolved by focusing on plant-based treatments for digestive diseases in humans and animals. The company faces financial challenges but continues to invest in new therapies and partnerships.

AI Generated • Apr 16, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

47

CEO

Lisa A. Conte, MBA

Website

www.jaguar.health

Headquarters

San Francisco, CA 94104, US

JAGX Financials

Key Financial Metrics (TTM)

Gross Margin

85.06%

Operating Margin

-86.26%

Net Income Margin

-115.39%

Return on Equity

764.53%

Return on Capital

-174.44%

Return on Assets

-91.15%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$6.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.86M

Volume

175.64K

Avg. Volume

94.80K

Financials (TTM)

Gross Profit

$25.15M

Operating Income

-$25.51M

EBITDA

-$37.87M

Operating Cash Flow

-$7.59M

Capital Expenditure

-$25.00K

Free Cash Flow

-$7.62M

Cash & ST Invst.

$7.28M

Total Debt

$43.78M

Jaguar Health Performance Analysis

Jaguar Health annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 11,956,000175.8%
20232023-12-31USD 9,761,000-18.4%
20242024-12-31USD 11,689,00019.8%
20252025-12-31USD 11,511,000-1.5%
Jaguar Health sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3034.6%
Q32025-09-303.5%
Q42025-12-314.9%
Q12026-03-31526.6%
Jaguar Health annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,899,528.75-59.0%
20232023-12-31USD -93,992.33-95.1%
20242024-12-31USD -4,574.07-95.1%
20252025-12-31USD -803.95-82.4%
Jaguar Health sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3038.6%
Q32025-09-3038.8%
Q42025-12-3147.0%
Q12026-03-3188.3%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$20.27M

+815.6%

Gross Profit

$19.11M

+1025.0%

Gross Margin

94.29%

N/A

Market Cap

$6.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$137.97K

N/A

Employees

47

N/A

Net Income

$8.85M

+184.6%

EBITDA

$9.94M

+198.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.28M

+27.9%

Total Debt

$43.78M

+14.2%

Accounts Receivable

$280.00K

-79.8%

Inventory

$7.82M

-25.9%

Long Term Debt

$11.97M

-38.4%

Short Term Debt

$31.81M

+68.2%

Return on Assets

-91.15%

N/A

Return on Invested Capital

7.84%

N/A

Free Cash Flow

$8.83M

+220.7%

Operating Cash Flow

$8.83M

+220.7%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SILOSilo Pharma, Inc.
$4.71-1.46%
INMInMed Pharmaceuticals Inc.
$1.58-0.63%
CNSPCNS Pharmaceuticals, Inc.
$4.91+3.59%
BDRXBiodexa Pharmaceuticals Plc
$2.05-3.76%

Trending Stocks

Symbol / CompanyPricePrice Chg
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$28.14+0.02%
AALAmerican Airlines Group
$15.03-0.04%
NUNu Holdings
$13.57-0.02%
AAPLApple
$333.49+0.00%

Questions About JAGX

What is the current price of Jaguar Health?

Jaguar Health is trading at $1.08 per share.

What is the 52-week range for Jaguar Health?

Over the past 52 weeks, Jaguar Health has traded between $1.02 and $92.75.

How much debt does Jaguar Health have?

As of the most recent reporting period, Jaguar Health reported total debt of $34.31M.

How much cash does Jaguar Health have on hand?

Jaguar Health reported $10.06M in cash and cash equivalents in its most recent financial results.

What is Jaguar Health’s dividend yield?

Jaguar Health does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services